TipRanks
BlossomHill Therapeutics, Inc. (BLSM)
NASDAQ:BLSM
US Market
BLSM
BlossomHill Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see BLSM full AI Analyst Report?

BlossomHill Therapeutics, Inc. (BLSM) Stock Forecast & Price Target

16 Followers
See the Price Targets and Ratings of:

BLSM Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
BlossomHill
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BLSM Stock 12 Month Forecast

Average Price Target

―
Based on 5 Wall Street analysts offering 12 month price targets for BlossomHill Therapeutics, Inc. in the last 3 months. The average price target is $35.40 with a high forecast of $40.00 and a low forecast of $30.00. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","28":"$28","41":"$41","21.5":"$21.5","34.5":"$34.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,21.5,28,34.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.59,20.236923076923077,21.883846153846154,23.53076923076923,25.177692307692308,26.824615384615385,28.47153846153846,30.11846153846154,31.765384615384615,33.41230769230769,35.059230769230766,36.706153846153846,38.35307692307693,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.59,19.883076923076924,21.176153846153845,22.46923076923077,23.762307692307694,25.055384615384614,26.34846153846154,27.64153846153846,28.934615384615384,30.22769230769231,31.52076923076923,32.81384615384616,34.106923076923074,{"y":35.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.59,19.467692307692307,20.345384615384614,21.223076923076924,22.10076923076923,22.978461538461538,23.856153846153845,24.73384615384615,25.611538461538462,26.48923076923077,27.366923076923076,28.244615384615386,29.122307692307693,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.99,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.59,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.00Average Price Target$35.40Lowest Price Target$30.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on BLSM
Michael Schmidt
Guggenheim
Guggenheim
$40
Buy
―
Reiterated
10/22/26
Analysts Offer Insights on NA Companies: Turn Therapeutics Inc (NASDAQ: TTRX) and BlossomHill Therapeutics, Inc. (NASDAQ: BLSM)
H.C. Wainwright Analyst forecast on BLSM
Robert Burns
H.C. Wainwright
H.C. Wainwright
$35
Buy
―
Reiterated
09/30/26
BlossomHill: Robust Emerging KRAS Franchise and Promising BH-501284 Data Support Unchanged $35 Price Target and Buy Rating
J.P. Morgan Analyst forecast on BLSM
Brian Cheng
J.P. Morgan
J.P. Morgan
$30
Buy
―
Reiterated
09/23/26
Analysts Conflicted on These NA Names: Guardian Metal Resources PLC Sponsored ADR (NYSE MKT: GMTL), BlossomHill Therapeutics, Inc. (NASDAQ: BLSM) and International Paper Co (NYSE: IP)
Leerink Partners Analyst forecast on BLSM
Andrew Berens
Leerink Partners
Leerink Partners
$36→$40
Buy
―
Reiterated
09/21/26
BlossomHill Therapeutics price target raised to $40 from $36 at LeerinkBlossomHill Therapeutics price target raised to $40 from $36 at Leerink
LifeSci Capital Analyst forecast on BLSM
Charles Zhu
LifeSci Capital
LifeSci Capital
$32
Buy
―
Reiterated
09/15/26
BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on BLSM
Michael Schmidt
Guggenheim
Guggenheim
$40
Buy
―
Reiterated
10/22/26
Analysts Offer Insights on NA Companies: Turn Therapeutics Inc (NASDAQ: TTRX) and BlossomHill Therapeutics, Inc. (NASDAQ: BLSM)
H.C. Wainwright Analyst forecast on BLSM
Robert Burns
H.C. Wainwright
H.C. Wainwright
$35
Buy
―
Reiterated
09/30/26
BlossomHill: Robust Emerging KRAS Franchise and Promising BH-501284 Data Support Unchanged $35 Price Target and Buy Rating
J.P. Morgan Analyst forecast on BLSM
Brian Cheng
J.P. Morgan
J.P. Morgan
$30
Buy
―
Reiterated
09/23/26
Analysts Conflicted on These NA Names: Guardian Metal Resources PLC Sponsored ADR (NYSE MKT: GMTL), BlossomHill Therapeutics, Inc. (NASDAQ: BLSM) and International Paper Co (NYSE: IP)
Leerink Partners Analyst forecast on BLSM
Andrew Berens
Leerink Partners
Leerink Partners
$36→$40
Buy
―
Reiterated
09/21/26
BlossomHill Therapeutics price target raised to $40 from $36 at LeerinkBlossomHill Therapeutics price target raised to $40 from $36 at Leerink
LifeSci Capital Analyst forecast on BLSM
Charles Zhu
LifeSci Capital
LifeSci Capital
$32
Buy
―
Reiterated
09/15/26
BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BlossomHill Therapeutics, Inc.

3 Months
Michael SchmidtGuggenheim
Success Rate
0/2 ratings generated profit
0%
Average Return
-11.80%
Copying Michael Schmidt's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -11.80% per trade.
1 Year
Michael SchmidtGuggenheim
Success Rate
0/2 ratings generated profit
0%
Average Return
-11.80%
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -11.80% per trade.
2 Years
Michael SchmidtGuggenheim
Success Rate
0/2 ratings generated profit
0%
Average Return
-11.80%
Copying Michael Schmidt's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -11.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BLSM Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
6
7
Buy
0
0
0
5
5
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
11
12
In the current month, BLSM has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BLSM average Analyst price target in the past 3 months is 35.40.
Each month's total comprises the sum of three months' worth of ratings.

BLSM Financial Forecast

BLSM Earnings Forecast

Next quarter’s earnings estimate for BLSM is -$0.93 with a range of -$1.15 to -$0.69. The previous quarter’s EPS was -$8.75. BLSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year BLSM has its overall industry.
Next quarter’s earnings estimate for BLSM is -$0.93 with a range of -$1.15 to -$0.69. The previous quarter’s EPS was -$8.75. BLSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year BLSM has its overall industry.
No data currently available

BLSM Sales Forecast

Next quarter’s sales forecast for BLSM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BLSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year BLSM has its overall industry.
Next quarter’s sales forecast for BLSM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BLSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year BLSM has its overall industry.

BLSM Stock Forecast FAQ

What is BLSM’s average 12-month price target, according to analysts?
Based on analyst ratings, BlossomHill Therapeutics, Inc.’s 12-month average price target is 35.40.
    What is BLSM’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for BLSM, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is BLSM a Buy, Sell or Hold?
        BlossomHill Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
          What is BlossomHill Therapeutics, Inc.’s price target?
          The average price target for BlossomHill Therapeutics, Inc. is 35.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $40.00 ,the lowest forecast is $30.00. The average price target represents N/A Increase from the current price of N/A.
            What do analysts say about BlossomHill Therapeutics, Inc.?
            BlossomHill Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
              How can I buy shares of BLSM?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.